Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Marqeta Inc (MQ) Price & Performance

BridgeBio Pharma IncTrade
Marqeta IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Marqeta Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Marqeta Inc trades at $15.52 (market cap $1.62B). The key difference: BridgeBio Pharma Inc is far larger — about 10.3× Marqeta Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.

BBIOMQ
Market Cap
$16.61B$1.62B
Sector
HealthTechnology
52-Week High
$90.17$26.00
52-Week Low
$47.29$15.04
Enterprise Value
$18.16B$939.53M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Marqeta Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Marqeta Inc

Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.

Read more on MQ